FORECAST: WET AGE-RELATED MACULAR DEGENERATION
1. Executive Summary, 2. Market Overview and Trends, 3. Market Definition and Methodology, 4. abicipar pegol, 5. Avastin (bevacizumab), 6. brolucizumab, 7. Eylea (aflibercept), 8. Fovista (pegpleranib), 9. Lucentis (ranibizumab), 10. squalamine, 11. Primary Research Methodology

TREATMENT: WET AGE-RELATED MACULAR DEGENERATION
12. Executive Summary, 13. Primary Research Methodology, 14. Disease Definition and Diagnosis, 15. Patient Segmentation, 16. Current Treatment Options, 17. Treatment Trends

EPIDEMIOLOGY: AGE-RELATED MACULAR DEGENERATION
18. Executive Summary, 19. Disease Background, 20. Sources and Methodology, 21. Forecast, 22. Epidemiologist Insight, 23. Strengths and Limitations

MARKETED DRUGS: WET AGE-RELATED MACULAR DEGENERATION
24. Executive Summary, 25. Product Overview, 26. Product profile: Avastin, 27. Product profile: Eylea, 28. Product profile: Lucentis, 29. Product profile: Macugen, 30. Product profile: Visudyne

PIPELINE: WET AGE-RELATED MACULAR DEGENERATION
31. Executive Summary, 32. Clinical Pipeline Overview, 33. Clinical Trial Design in Wet AMD, 34. The Future of Treatment in Wet AMD, 35. Product profile (late stage): Fovista, 36. Product profile (late stage): abicipar pegol, 37. Product profile (late stage): brolucizumab, 38. Product profile (late stage): squalamine